Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study
机构:[1]Chinese PLA Gen Hosp 301 Hosp, Dept Cardiol, Beijing, Peoples R China;[2]Chinese PLA Gen Hosp 301 Hosp, Dept Hematol, Beijing, Peoples R China;[3]Natl Ctr Cardiovasc Dis, Cardiovasc Inst, Beijing, Peoples R China;[4]FuWai Hosp, Beijing, Peoples R China;[5]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China;临床科室心脏内科中心首都医科大学附属安贞医院[6]Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China;[7]Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden;[8]Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden;[9]China PLA Gen Hosp, Dept Cardiol, 28 Fuxing Rd, Beijing 100853, Peoples R China
Purpose: Limited data exist on the use of statins in Chinese patients with coronary artery disease (CAD) treated with percutaneous coronary intervention (PCI). We therefore conducted this study to observe the usage trend and the effectiveness of statins on LDL-C goal attainment and other lipid parameters among PCI-treated patients. Methods: This multicenter, retrospective, observational, longitudinal cohort study was conducted in PCI-treated patients with CAD between July 1, 2011, and February 28, 2015. Primary study outcomes included statin treatment pattern after PCI and proportion of patients achieving target (LDL-C) levels 1 month after PCI and initiating statin therapy. Findings: Data were analyzed for 2708 patients (mean age, 59 [10] years; median body mass index, 25.6 [4.0] kg/m(2)). From baseline to the end of 1 month, atorvastatin and rosuvastatin were the most prescribed statins; 20 mg and 10 mg were the most prescribed doses and therefore chosen for efficacy comparisons. In patients without dose changes, LDL-C reduction with rosuvastatin 10 mg was significantly greater compared with atorvastatin 20 mg (-0.67 mmol/L [from 2.44 mmol/L to 1.77 mmol/L] vs 0.54 mmol/L [from 2.40 mmol/L to 1.86 mmol/L]; P = 0.008). However, there was no difference in HDL-C, triglyceride, or total cholesterol values between groups. Age and LDL-C levels at baseline were significantly associated with target LDL-C achievement. (C) 2017 Published by Elsevier HS Journals, Inc.
基金:
AstraZenecaAstraZeneca; AstraZeneca Pharmaceutical Company Ltd.AstraZeneca
第一作者机构:[1]Chinese PLA Gen Hosp 301 Hosp, Dept Cardiol, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Chinese PLA Gen Hosp 301 Hosp, Dept Cardiol, Beijing, Peoples R China;[9]China PLA Gen Hosp, Dept Cardiol, 28 Fuxing Rd, Beijing 100853, Peoples R China
推荐引用方式(GB/T 7714):
Chen Yundai,Li Dandan,Jing Jing,et al.Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study[J].CLINICAL THERAPEUTICS.2017,39(9):1827-1839.doi:10.1016/j.clinthera.2017.07.042.
APA:
Chen, Yundai,Li, Dandan,Jing, Jing,Yan, Hongbing,Liu, Jinghua...&Varenhorst, Christoph.(2017).Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study.CLINICAL THERAPEUTICS,39,(9)
MLA:
Chen, Yundai,et al."Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study".CLINICAL THERAPEUTICS 39..9(2017):1827-1839